Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNERGY OSA
2023-510519-20-00Phase 2Completed
- Sponsor
- Region Västra Götaland
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of sultiame and Placebo-COD Research Private Ltd in obstructive sleep apnea hypopnea syndrome (OSAHS) (2 arms), sponsored by Region Västra Götaland. Primary endpoint: Reduction in apnea-hypopnea index (AHI3a). Started Dec 2024; status: completed.
02
Drugs
sultiamePlacebo-COD Research Private Ltd
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on 2023-510519-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510519-20-00.